Login to Your Account

Overseas Sites Join Genzyme's Phase II Gene Therapy PAD Bid

By Randall Osborne

Friday, May 19, 2006
Researchers in the UK and Germany enrolled their first patients in Phase II trials to test a gene therapy developed by Genzyme Corp. targeting intermittent claudication, a common form of peripheral arterial disease (PAD) that causes pain and difficulty walking. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription